United States securities and exchange commission logo





                             January 12, 2024

       Zhengbin (Bing) Yao, Ph.D.
       Chief Executive Officer
       ArriVent Biopharma, Inc.
       18 Campus Boulevard, Suite 100
       Newtown Square, PA 19073

                                                        Re: ArriVent Biopharma,
Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed January 5,
2024
                                                            File No. 333-276397

       Dear Zhengbin (Bing) Yao:

                                                        We have reviewed your
registration statement and have the following comment.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe a comment applies to your
facts and circumstances
       or do not believe an amendment is appropriate, please tell us why in
your response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this letter, we may have additional comments.

       Form S-1 filed January 5, 2024

       Management's Discussion and Analysis of Financial Condition and Results
of Operations
       Determination of Fair Value of Our Common Stock, page 108

   1.                                                   We note your response
to prior comment eight, as well as your disclosure related to
                                                        options granted on
January 1 and January 4, 2024 on page 108. Please revise this section
                                                        to discuss how the
estimated fair value per common share on grant date for these options
                                                        compare to the low end
and midpoint of estimated price range when available. Revise to
                                                        identify the extent to
which any incremental increase in value between the grant date and
                                                        the date of the filing
is due to specific and identifiable business activities or events.
               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.
 Zhengbin (Bing) Yao, Ph.D.
ArriVent Biopharma, Inc.
January 12, 2024
Page 2

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Li Xiao at 202-551-4391 or Kevin Vaughn at 202-551-3494
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Chris Edwards at 202-551-6761 or Suzanne Hayes at 202-551-3675 with any other
questions.



                                                           Sincerely,
FirstName LastNameZhengbin (Bing) Yao, Ph.D.
                                                           Division of
Corporation Finance
Comapany NameArriVent Biopharma, Inc.
                                                           Office of Life
Sciences
January 12, 2024 Page 2
cc:       John Rudy
FirstName LastName